Botulinum Toxin Injection for Treatment of Gastroparesis
- PMID: 30396531
- PMCID: PMC6223662
- DOI: 10.1016/j.giec.2018.08.007
Botulinum Toxin Injection for Treatment of Gastroparesis
Abstract
Refractory gastroparesis is among the most difficult therapeutic challenges in gastroenterology. Pyloric dysfunction has been described in a subset of patients with gastroparesis, prompting experimentation with botulinum toxin injections into the pylorus, which is relatively safe and has been successfully used in other gastrointestinal disorders. However, causality between pyloric dysfunction and symptoms of gastroparesis has never been demonstrated. Although several open-label studies showed initial promise, 2 randomized clinical trials failed to elicit a difference in clinical outcomes in botulinum toxin versus placebo. Based on current evidence, further use of botulinum toxin for gastroparesis is discouraged outside of a research trial.
Keywords: BOTOX; Botulinum neurotoxin; Gastroparesis; Pyloric dysfunction; Pylorospasm.
Copyright © 2018 Elsevier Inc. All rights reserved.
References
-
- Mearin F, Camilleri M, Malagelada J-R. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986;90:1919–1925. - PubMed
-
- Feldman M, Smith HJ, Simon TR. Gastric emptying of solid radiopaque markers: studies in healthy subjects and diabetic patients. Gastroenterology 1984;87:895–902. - PubMed
-
- Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Digestive Diseases and Sciences 1985;30:1–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
